Elizabeth Gaughan - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Elizabeth Gaughan

Showing results (11-20 of 13) with videos related to

Pageof 2

Sort By:

You have reached the last page of results.This site can display upto 13 results.

Cancer Research Communications|April 10, 2026

Randomized phase I/II clinical trial of a melanoma helper peptide vaccine with or without systemic agonistic anti-CD27 antibody (varlilumab)Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan, et al.

Journal for Immunotherapy of Cancer|May 10, 2020

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanomaVictor H Engelhard, Rebecca C Obeng, Kara L Cummings, et al.

Therapeutic Advances in Medical Oncology|June 19, 2025

Proceedings of the seventh annual Women in Melanoma ConferenceYana G Najjar, Marlana Orloff, Tara C Mitchell, et al.

Pageof 2

Search research articles

Showing results (11-20 of 13) with videos related to

Sort By:

Pageof 2

You have reached the last page of results.This site can display upto 13 results.

Cancer Research Communications|April 10, 2026

Randomized phase I/II clinical trial of a melanoma helper peptide vaccine with or without systemic agonistic anti-CD27 antibody (varlilumab)Emily K Ninmer, Gina R Petroni, Elizabeth Gaughan, et al.

Journal for Immunotherapy of Cancer|May 10, 2020

MHC-restricted phosphopeptide antigens: preclinical validation and first-in-humans clinical trial in participants with high-risk melanomaVictor H Engelhard, Rebecca C Obeng, Kara L Cummings, et al.

Therapeutic Advances in Medical Oncology|June 19, 2025

Proceedings of the seventh annual Women in Melanoma ConferenceYana G Najjar, Marlana Orloff, Tara C Mitchell, et al.

Pageof 2